Business Wire

THE-OPEN-GROUP

15.12.2020 15:02:15 CET | Business Wire | Press release

Share
The Open Group: Hybrid Big Data Technologies Developed From €4.5M European Union Research Project Enter Final Industrial Evaluations

The Open Group , the vendor-neutral technology consortium, and the University of York today announced a partnership with a consortium of leading European research organizations, software developers, and industrial big data users. Together, they will make hybrid big data accessible and easy to integrate within new applications and services through developing and evolving next generation technologies.

With support from the European Union, the Polyglot and Hybrid Persistence Architectures for Big Data Analytics (TYPHON) project has already invested €4.5 million (US$5.3 million) into advanced technology development. This funding has enabled the rapid creation of applications that bridge the many formats and architectures used to store data today. The integrated platform is currently undergoing first deployments within major organizations across the Telecom, Banking, Automotive, and Aerospace industries, and is being made widely available in open source format. By implementing the new technologies, organizations are able to enhance the productivity of their data architects, reduce development time and costs, and deliver new applications and services that make full use of existing big data stores.

Today’s development teams face substantial challenges when it comes to ensuring hybrid big data applications and services are designed coherently, which requires capturing a range of different formats that data is held within. To overcome these complexities, the TYPHON project has built a set of tools for developing, querying, evolving, analyzing, and monitoring hybrid big data polystores. These polystores readily combine numerous types of underlying storage technologies, including relational, graph-based, document-based, natural language, and big data islands.

David Lounsbury, Chief Digital Officer, The Open Group said: “The TYPHON project has brought together a range of industry experts who have collaborated to streamline the time intensive process of implementing intricate big data solutions. By connecting many different storage formats, the new technologies enable developers to deliver applications capable of effectively utilizing big data assets within organizations. The Open Group has a long-standing history of working with the University of York on complex systems. Together, we can provide the expertise and guidance needed to drive these technologies through final industrial evaluations.”

The advanced tools provide big data systems developers with:

  • Technologies for designing hybrid polystores, taking into account the structure of the data, the availability, partitioning, and consistency requirements of different subsets of the data, and the available deployment resources
  • Novel algorithms for transforming hybrid polystore design models into preconfigured optimized virtual machines which can be deployed on cloud infrastructure
  • An extensible high-level language for querying and modifying data stored in hybrid polystores, as well as capabilities for translating high-level queries into efficient native queries
  • A high-performance framework for publishing and processing data access and updating events to facilitate real-time monitoring and predictive analytics
  • Technologies for evolving the organization and distribution of data in hybrid polystores, along with tools for monitoring use of polystores for enhanced evolution

Coordinated by The Open Group with technical leadership from the University of York, which has directed the advanced research, the TYPHON consortium includes:

“With the availability of the TYPHON Modelling Language, Query Language, Deployment Language, and tools for creating, monitoring, and evolving new hybrid big data polystores, software developers can now rapidly create next generation applications and systems,” said Professor Dimitris Kolovos, University of York. “Through addressing key industry challenges, the TYPHON project is dedicated to ensuring hybrid big data solutions are designed, assembled, and configured consistently - ultimately enabling organizations to unlock the power of data.”

The technological advances and innovations resulting from the TYPHON project, as well as the final versions of the technologies in open source format are publically available via the project website: www.typhon-project.org

The TYPHON project receives funding under the European Union Horizon 2020 Research and Innovation Programme, an initiative of the European Community created to foster European research and the development of new technologies, applications, and industries.

-ENDS-

About The Open Group

The Open Group is a global consortium that enables the achievement of business objectives through technology standards. Our diverse membership of more than 800 organizations includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. Further information on The Open Group can be found at www.opengroup.org .

About the University of York

The Department of Computer Science at the University of York prepares graduates for the workplace at all levels through close collaboration with industry. The majority of the research work carried out has been classed as world-leading or internationally excellent and is focused around seven themes which align our academic strengths to best meet the greater scientific, social and environmental challenges of our time. Research teams work across disciplines within academia and industry with a strong focus placed on transforming research results into tangible solutions for industry. Further information on the University of York can be found at www.cs.york.ac.uk .

# # #

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye